| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/24/2023 | -22.41% | Morgan Stanley | $25 → $26 | Maintains | Equal-Weight |
| 01/10/2023 | 13.4% | Needham | $35 → $38 | Maintains | Buy |
| 11/16/2022 | 10.41% | Barclays | $35 → $37 | Maintains | Overweight |
| 11/09/2022 | -25.4% | Morgan Stanley | $27 → $25 | Maintains | Equal-Weight |
| 10/11/2022 | -19.43% | Morgan Stanley | → $27 | Initiates Coverage On | → Equal-Weight |
| 09/22/2022 | -1.52% | Goldman Sachs | → $33 | Initiates Coverage On | → Buy |
| 09/09/2022 | -10.47% | Mizuho | $26 → $30 | Maintains | Buy |
| 09/09/2022 | 4.45% | Barclays | $22 → $35 | Maintains | Overweight |
| 09/09/2022 | -13.46% | HC Wainwright & Co. | $25 → $29 | Maintains | Buy |
| 09/09/2022 | 4.45% | Needham | $25 → $35 | Maintains | Buy |
| 08/25/2022 | -28.38% | Wells Fargo | $17 → $24 | Maintains | Equal-Weight |
| 10/26/2021 | -34.35% | Barclays | $33 → $22 | Maintains | Overweight |
| 10/25/2021 | -49.27% | Wells Fargo | → $17 | Downgrades | Overweight → Equal-Weight |
| 10/18/2021 | -25.4% | Needham | $45 → $25 | Maintains | Buy |
| 10/18/2021 | -46.28% | HC Wainwright & Co. | $26 → $18 | Maintains | Buy |
| 10/13/2021 | -22.41% | HC Wainwright & Co. | $35 → $26 | Maintains | Buy |
| 08/06/2021 | -1.52% | Barclays | $32 → $33 | Maintains | Overweight |
| 02/23/2021 | 4.45% | HC Wainwright & Co. | $33 → $35 | Maintains | Buy |
| 01/08/2021 | 34.29% | Needham | $42 → $45 | Maintains | Buy |
| 10/15/2020 | 25.34% | Needham | $36 → $42 | Maintains | Buy |
| 04/16/2020 | -7.49% | Stifel | $35 → $31 | Maintains | Buy |
| 04/01/2020 | 4.45% | Mizuho | $39 → $35 | Maintains | Buy |
| 03/27/2020 | -28.38% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
| 03/23/2020 | -55.24% | Goldman Sachs | $32 → $15 | Downgrades | Buy → Neutral |
| 02/25/2020 | 19.37% | Piper Sandler | $37 → $40 | Reiterates | → Overweight |
| 02/25/2020 | 7.43% | Needham | $32 → $36 | Maintains | Buy |
| 02/18/2020 | 10.41% | Piper Sandler | $38 → $37 | Maintains | Overweight |
| 01/23/2020 | 16.38% | Mizuho | $34 → $39 | Maintains | Buy |
| 12/02/2019 | -25.4% | Goldman Sachs | → $25 | Initiates Coverage On | → Buy |
| 10/30/2019 | -40.32% | Wells Fargo | $12.5 → $20 | Upgrades | Market Perform → Outperform |
| 06/11/2019 | -16.44% | Barclays | → $28 | Initiates Coverage On | → Overweight |
| 02/15/2019 | — | Wells Fargo | Initiates Coverage On | → Market Perform | |
| 02/14/2019 | -25.4% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 01/29/2019 | 49.21% | Stifel | → $50 | Initiates Coverage On | → Buy |
| 11/16/2018 | 22.35% | Guggenheim | → $41 | Upgrades | Neutral → Buy |
| 09/17/2018 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 03/05/2018 | 79.05% | Goldman Sachs | → $60 | Initiates Coverage On | → Buy |
What is the target price for Revance Therapeutics (RVNC)?
There is no price target for Revance Therapeutics
What is the most recent analyst rating for Revance Therapeutics (RVNC)?
There is no analyst for Revance Therapeutics
When is the next analyst rating going to be posted or updated for Revance Therapeutics (RVNC)?
There is no next analyst rating for Revance Therapeutics
Is the Analyst Rating Revance Therapeutics (RVNC) correct?
There is no next analyst rating for Revance Therapeutics